

What is claimed is:

1. A liquid conjugate comprising a bioactive agent and an absorbable liquid polymer, said bioactive agent and said absorbable liquid polymer being at least partly ionically bonded together to form said liquid conjugate.
- 5 2. The liquid conjugate of Claim 1 wherein at least 50 percent of said bioactive agent and said absorbable liquid polymer is ionically bonded together.
3. The liquid conjugate as in Claim 1 wherein the bioactive agent is a basic bioactive molecule and the polymer is a polycarbonate, polyester-carbonate, or polyester carrying one or more carboxyl group.
- 10 4. The liquid conjugate as in Claim 1 wherein the liquid polymer component is a carboxyl-bearing segmented copolyester comprising a polyalkylene oxide segment.
5. The liquid conjugate as in Claim 1 wherein the liquid polymer component is a carboxyl-bearing homopolymeric or copolymeric polyalkylene oxide.
6. The liquid conjugate composition as in Claim 1 wherein said bioactive agent
15 is ziprasidone and said liquid polymer is a carboxyl-bearing block/segmented copolymer comprising a polyalkylene carbonate and a polyalkylene oxide segment/block.
7. A pharmaceutical composition comprising the liquid conjugate of Claim 1 and a pharmaceutically acceptable carrier.
8. The pharmaceutical composition of Claim 7 wherein said
20 pharmaceutically acceptable carrier is for controlled release or immediate release.
9. The pharmaceutical composition of Claim 7 wherein said bioactive agent is an aryl-heterocyclic compound.
10. The pharmaceutical composition of Claim 9 wherein said aryl-heterocyclic compound is ziprasidone.
- 25 11. The pharmaceutical composition of Claim 7 wherein said liquid polymer is (i) a carboxyl-bearing polyester, copolyester, polyalkylene carbonate, copolyester carbonate or combinations thereof; or (ii) an amine-bearing polyester, copolyester, polyalkylene carbonate, polyether carbonate, polyether, copolyester-carbonate or combinations thereof.
12. The pharmaceutical composition of Claim 7 wherein said bioactive agent is
30 ziprasidone and said liquid polymer is a carboxyl-bearing block/segmented copolymer comprising a polyalkylene carbonate and a polyalkylene oxide segment/block.
13. A composition comprising a solid bioactive agent and one or more liquid polymers, wherein said bioactive agent and said liquid polymer or polymers comprise moieties, wherein said moieties of said bioactive agent interact in said composition with said
35 moieties of said liquid polymer or polymers, wherein at least about 50 percent of said interaction is ionic bonding.